Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.86 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986264 | 1.00 | ALOX5 (0.86) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrocurcumin SCHEMBL29370299 | 0.92 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrocurcumin SCHEMBL29372158 | 0.92 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrocurcumin SCHEMBL284877 | 0.92 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL28355932 | 0.89 | ALOX5 (0.88) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307533 | 0.88 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307817 | 0.88 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL4005549 | 0.88 | ALOX5 (0.86) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL4002776 | 0.88 | ALOX5 (0.67) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Zingerone SCHEMBL14763994 | 0.88 | ALOX5 (0.74) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901618-B1 | HYDROXYPHENYLALKADIONES AND THEIR USE FOR MASKING BITTER TASTE AND/OR FOR INTENSIFYING SWEET TASTE | SYMRISE GMBH & CO KG (DE) | 2009-06-17 | — | — | EP | claimed |
| US-20080227866-A1 | Hydroxyphenylalkadiones and Their Use for Masking Bitter Taste and/or for Intensifying Sweet Taste | SYMRISE GMBH & CO. KG (DE) | 2008-09-18 | — | — | US | claimed |
| EP-1901618-A1 | HYDROXYPHENYLALKADIONES AND THEIR USE FOR MASKING BITTER TASTE AND/OR FOR INTENSIFYING SWEET TASTE | Symrise GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007003527-A1 | HYDROXYPHENYLALKADIONES AND THEIR USE FOR MASKING BITTER TASTE AND/OR FOR INTENSIFYING SWEET TASTE | SYMRISE GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | claimed |
| CN-110229056-B | Novel curcumin analogue and preparation method and application thereof | 天津科技大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-2368442-B1 | Use of hesperetin for enhancing the sweet taste | SYMRISE AG (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-1909599-B1 | USE OF HESPERETIN FOR ENHANCING THE SWEET TASTE | SYMRISE AG (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2368442-A2 | Use of hesperetin for enhancing the sweet taste | Symrise AG (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110111068-A1 | Inhibitors of cognitive decline | CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS FOUNDATION, CHANNEL ISLANDS ALZHEIMER'S INSTITUTE | 2011-05-12 | — | — | US | disclosed |
| US-7723377-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723377-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1998636-B1 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS | SYMRISE GMBH & CO KG (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-1955601-A1 | Use of propenylphenylglycosides for intensifying sweet sensory impressions | Symrise GmbH & Co. KG (DE) | 2008-08-13 | — | — | EP | disclosed |
| EP-1901618-A1 | HYDROXYPHENYLALKADIONES AND THEIR USE FOR MASKING BITTER TASTE AND/OR FOR INTENSIFYING SWEET TASTE | Symrise GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003527-A1 | HYDROXYPHENYLALKADIONES AND THEIR USE FOR MASKING BITTER TASTE AND/OR FOR INTENSIFYING SWEET TASTE | SYMRISE GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-5208251-A | Compounds for antiinflammatory agents, antiallergens, antiarthritic, antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0245825-B1 | STYRYL PYRAZOLES, ISOXAZOLES AND ANALOGS THEREOF HAVING ACTIVITY AS 5-LIPOXY-GENASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4924002-A | REACTION WITH MOLYBDENUM CARBONYL AND HYDRAZINE | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4877881-A | SUNSCREEN | WARNER-LAMBERT COMPANY (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0245825-A1 | Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111068-A1 | Inhibitors of cognitive decline | NAA50, NOS1, NOS2 | ALOX5 16/4885OR51E2 1095/4885CYP3A4 730/4885 |
| US-20080227866-A1 | Hydroxyphenylalkadiones and Their Use for Masking Bitter Taste and/or for Intensifying Sweet Taste | TAS2R1, TAS2R5, TAS2R50 | ALOX5 1881/4885OR51E2 30/4885CYP3A4 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.